Institution Directory

Clinical trials at UPMC (University of Pittsburgh)

Sites in Pittsburgh, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1600

Shown on this page

Current sort

Live official records

Conditions: HIV
Interventions: DV201P-RNA, DV202B1-RNA; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Atlanta, Georgia • Decatur, Georgia • Boston, Massachusetts + 4 more

Conditions: Opioid Use Disorder, Pregnancy Related
Interventions: Buprenorphine/ Methadone exposure; Drug
Lead sponsor: Ilana Hull; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cardiac Arrest (CA), Heart Arrest, Heart Arrest, Out-Of-Hospital
Interventions: Transfer to specialty care, Usual care; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 1,618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pain Management, Postoperative Pain
Interventions: Psilocybin (Usona Institute), Postoperative analgesia; Drug
Lead sponsor: Trent Emerick; Other
Eligibility: 25 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Heart Defect, Congenital
Interventions: Xeltis Bioabsorbable Pulmonary Valved Conduit; Device
Lead sponsor: Xeltis; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Hollywood, Florida + 4 more

Conditions: Germ Cell Tumors
Interventions: Paclitaxel, Ifosfamide, Cisplatin, Mesna, Bleomycin, Etoposide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 10 more

Conditions: Obstructive Sleep Apnea of Adult, Preeclampsia, Obstetrical Complications
Interventions: Continuous Positive Airway Pressure, Sleep Advice Control; Device · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Conditions: Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
Interventions: Intravenously administered pooled human immunoglobulin (IVIG); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Pittsburgh, Pennsylvania + 2 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 19 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Iowa City, Iowa • Kansas City, Kansas • New Orleans, Louisiana + 11 more

Conditions: Recurrent Acute Pancreatitis, Chronic Pancreatitis
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • Stanford, California • Columbus, Ohio + 1 more

Conditions: Cancer, Melanoma (Skin Cancer), Immunotherapy
Interventions: Digital remote monitoring intervention, Usual Care; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 142
States / cities: Auburn, California • Berkeley, California • Fremont, California + 116 more

About this UPMC (University of Pittsburgh) institution page

What this page lists: ClinicalTrials.gov records that list UPMC (University of Pittsburgh) in Pittsburgh, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UPMC (University of Pittsburgh)

Filter and sort this campus

Live official records

Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV

Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

The Effect of SPecialty cAre on Recovery From Cardiac Arrest Trial (the SPARC Trial)

Psilocybin After Trauma Surgery for Pain

Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis

Investigating Real-Time Immunotherapy Symptoms Study

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

About this UPMC (University of Pittsburgh) institution page